Atlas Trials

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Clinical trial NCT04263298 · RECRUITING

Trial details

NCT number
NCT04263298
Sponsor
Herui Yao
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2018-05-01
Primary completion
2025-05-01
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.